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Introduction
Newborn bloodspot screening (NBS) for cystic fibrosis (CF) is now established in many developed countries, [1] [2] [3] [4] as early detection improves nutritional status, height and weight gain. 5 CF is the largest single disease contributor to screen positive NBS results in many jurisdictions, and is an exemplar case for understanding the impact of expanded NBS. Approximately 30% of screen positive cases/year identified in Ontario are attributable to CF, 6 the majority of which are false positive (FP) upon confirmatory testing; as many as 80% of these are CF carriers. 6, 7 As part of efforts to balance benefits and burdens of population screening, the impact of FP results has long garnered attention. In the context of NBS, the concern dates back to 1968 when "PKU-Anxiety Syndrome" described the distressing experience of receiving FP results for phenylketonuria (PKU). 8 Evidence has since accumulated suggesting that parents may experience a range of reactions related to receiving positive CF NBS results. Tluczek et al 9 found that prior to confirmatory CF sweat testing, up to 43% of parents who had received an abnormal screening result experienced clinically significant depressive symptoms. However, after the sweat test, parents whose infants were found to be CF carriers did not differ from screen negative controls. Parents' prior knowledge of NBS, CF, and their own carrier status as well as the clinician's approach to informing them influenced this emotional reaction. 9 Similarly, others have found that majorities of parents (74-96%) reported high anxiety in reaction to positive NBS results but upon receiving normal sweat test results, majorities (64-86%) were relieved. 10, 11 While detected anxiety appears to be transient, [9] [10] [11] one to six years after identification, up to 29% of parents report worry about the health of their carrier child as well as potential difficulties posed for future relationships. Stress scores are also higher at one year post-disclosure among parents who received CF carrier versus negative results . [12] [13] Parsons et al, 14 however, found that by 6 months post-disclosure, there was no evidence that carrier identification was associated with a compromised mother-baby relationship. Other survey and qualitative data suggest that, ultimately, the majority of parents feel better knowing their child's CF carrier status. 9, 15 While the negative psychosocial impact of FP results appears to be transient, vulnerability remains a concern. Responding to this evidence and as a broader measure of quality, Newborn Screening Ontario developed programmatic recommendations to minimize delay to confirmatory testing, ensure trained health professionals are communicating results to parents, and build partnerships with primary care providers. Presented herein are quantitative and qualitative data that reflect upon maternal lived experiences soon after CF NBS FP result notification in the context of a centralized provincial program.
Participants and Methods
In Ontario, CF NBS involves a two-step process of measuring immunoreactive trypsinogen (IRT) followed by screening the CF transmembrane regulator gene for 39 mutations. 6 Infants with identified to have one CF mutation or an IRT > 99th centile are referred for diagnostic sweat chloride testing. In collaboration with the CF clinic at the Hospital for Sick Children (SickKids) in Toronto (largest pediatric tertiary care centre in Canada), we conducted selfadministered postal surveys of mothers of CF screen positive infants and a control sample, at 2 months following the infant's birth (T1) and one year later (T2). We also conducted semistructured interviews with a sub-sample of FP survey respondents at both time-points. While the complete screen positive population included true-, false-, and inconclusive-positive infants, we focus herein on the longitudinal results from the T1 FP responder group. Research Ethics Boards at SickKids, The Children's Hospital of Eastern Ontario, and The University of Toronto approved this work.
Sample and Recruitment
T1 recruitment of mothers was prospective over 18 months. The full population of mothers of CF screen positive infants seen at SickKids, aged 4-6 weeks (i.e. confirmatory testing complete), were eligible to participate. Those facing extenuating perinatal circumstances, those undergoing adoption proceedings, mothers of multiples, and mothers facing a significant language barrier were excluded. The control sample (3:1 control:case ratio) included a random sample of mothers of infants in the population who screened negative for all disorders included in Ontario's NBS panel, resided within the SickKids catchment area (i.e. according to postal code boundaries), and were 4-6 weeks old. Mothers of infants with an unsatisfactory bloodspot were excluded as were mothers of infants facing adoption proceedings, blood transfusion, prematurity (i.e. gestational age <36 weeks), early death, or > 60 day delay between date of birth and date of bloodspot collection.
Mothers of FP infants were notified of the study verbally and with a letter of introduction at the conclusion of their confirmatory sweat-testing appointment (4-6 weeks post-birth). Four weeks following this notification, potential participants who had not opted out were mailed a survey package. One follow-up package was sent one month later. For screen negative controls, mothers were notified of the study by mail, 4 weeks following birth. Potential controls who had not opted out were mailed a survey package and invited to participate, with three additional contacts (at 2-week intervals) for non-responders (i.e. modified Dillman method). 15 In response to a poorer than expected response rate at three months (presumed attributable to the young age of the baby at initial contact), the recruitment timelines were slightly extended (Box 1). The overall shorter recruitment timeline for FP cases compared to controls reflects the differential burden appropriate to clinical and non-clinical study populations. 16, 17 Completion of the questionnaire constituted consent to participate. At T2, one year following the completion or administration of the T1 survey, T1 responders and non-responders were mailed a slightly modified second survey. The recruitment and survey administration process was the same as that used at T1 with FP notification mail.
Data Collection and Analysis: Survey
The survey package included (i) a team-developed, self-administered questionnaire gauging CF knowledge, understanding of screening result, experiences with the notification process, (ii) 5 self-administered measures of psychosocial response, (iii) demographic questions, and (iv) a study information sheet, a consent to re-contact form for the qualitative interview, and a small financial incentive ($2 coffee coupon). The questionnaire was adapted from existing instruments developed for NBS and CF research 9-15, 21-22, 28-48 and pilot tested with new parents recruited from the Greater Toronto Area (N=15) through an online mothers' group. The core of the questionnaire was consistent across FP and control groups; non-applicable FP related content was removed from the control group questionnaire. The measures of psychological response included: (i) the State Subscale of the State Trait Anxiety Inventory (STAI) as a measure of anxiety, [28] [29] [30] [31] [32] (ii) the Brief Symptom Inventory (BSI) as a measure of distress, [33] [34] [35] [36] [37] [38] [39] (iii) the Child Vulnerability Scale (CVS) as a measure of maternal perception of infant vulnerability, [40] [41] [42] [43] (iv) a modified version of the Parental Perceptions of Uncertainty in Illness Scale (PPUS) as a measure of perceived uncertainty related to childhood illness, [44] [45] [46] [47] and ( Questionnaire data were manually entered into IBM SPSS Statistics version 18. Where the data entry error rate was >0.50%, full double data entry was performed. We report cross-sectional analyses for T1 and repeated measures analyses for the subsample of respondents who completed both T1 and T2 questionnaires. We quantified the overall pattern of responses, reporting proportions with 95% CIs for discrete variables and means with standard deviations for continuous variables, for each of the FP and screen negative groups. T-tests were performed on log-transformed STAI, CVS, and PPUS scale data and on BSI t-scores. Since MWS scores were highly skewed and did not respond favorably to power transformation, non-parametric tests were used to gauge group differences. For T1 data, linear regression was performed to examine the association of FP status with anxiety, distress, vulnerability, and uncertainty, controlling for maternal characteristics where there was a difference between groups. Given multiple comparisons in the regression models, a more stringent p value (p<0.01) was used to determine statistical significance. We then performed two-factor mixed ANOVAs to gauge the effect of time on anxiety, distress, vulnerability, and uncertainty. Maternal worry was analyzed separately because data were concentrated at a score of 10. We subtracted 10 from each score and treated the data as count data in order to compare screen negative and FP groups at each time point. Negative binomial regression was used for the subsample for whom we had T1 and T2 worry data (total n=255), adjusting for the same confounders as the T1 linear regressions. At T2, a repeated measures negative binomial regression was performed on worry data.
Data Collection and Analysis: Interviews
Following our receipt of completed questionnaires, we conducted semi-structured, open-ended interviews with all mothers of FP infants who agreed (by checking a box on the questionnaire).
Interviews were conducted by telephone where face-to-face was not preferred, or because of excess cost of travel to a distant location. The interview guide queried mothers' experiences receiving results, and their understanding of screen positive and confirmatory sweat testing results. Interviews were taped, transcribed and coded. We used a thematic approach, applying and modifying pre-existing codes from the interview guide pertaining to the experience of receiving FP results, and allowed new themes to emerge from the data using constant comparison. Through an iterative process, codes were refined and inconsistencies were resolved through discussion. 49, 50 We used T1 interviews to identify themes and then searched for confirming/disconfirming evidence and persistence of experience in T2 interviews.
Results

Quantitative findings
Characteristics of survey respondents
Of 246 eligible mothers of infants who received FP NBS results, 134 responded (RR=54.5%) to the survey, and of 869 eligible mothers of screen negative infants, 410 responded (RR=47.2%).
Among mothers of FP infants, we report on 134 mothers (T1) of whom 82 (T2) completed T1 and T2 surveys. According to mothers, 141 (65.2%) of these infants were confirmed to be carriers, 44 (20.4%) were confirmed non-carriers, and for 31 (14.4%), carrier status was unknown. Among screen negative infants, we report on 410 mothers (T1) of whom 179 (T2) completed T1 and T2 surveys.
The characteristics of our survey samples are reported in Table 1 . At T1, compared to controls, a greater proportion of mothers of FP infants reported living in rural areas (p<0.05), fewer had completed undergraduate (or higher) degrees (p=0.02) and more reported that the index infant was their first child (p=0.01). Compared to an Ontario-based CF population, our participants were similar in education and income levels. 51 
Psychosocial outcomes
In both the FP and control groups at T1 and T2, mean anxiety, distress, and vulnerability scores were low relative to reference means or clinical cut-offs where these were available from the literature (Box 2, Table 2) , and not significantly different between groups (Table 2) . While uncertainty scores were significantly different between groups at T1, the control group reported more uncertainty than the cases (p=0.03; Table 2 ). Results of linear regression showed that FP status did not predict anxiety, distress, vulnerability or uncertainty at T1, controlling for relevant maternal characteristics (Table 3) . Repeated measures analyses indicated no change in psychosocial response over time, except that uncertainty scores remained higher among controls at T2 (p=0.03; data not shown).
Maternal worry scores were significantly higher among mothers of FP infants compared to controls at T1 and T2 (p=0.002, p=0.004; Table 2 ). When the worry scale item related to carrier children having a harder time making reproductive choices was removed (worry_revised), the significance of this effect disappeared. Adjusting for maternal characteristics, the negative binomial regression at T1 (using the 10-item worry scale) showed that FP status did not predict worry. Over time, worry decreased (p=0.01), and there was no difference between FP and controls on T2 worry scores (data not shown).
Self-reported experiences
With respect to the notification system itself, 61% of mothers in the FP group were notified of their results from their primary care provider and 39% were notified by a genetic counselor.
Only 13% indicated that they would have preferred to receive this notification from someone else; of those 47% indicated a preference for their primary care provider and 53% indicated a preference for a counselor from the screening program. 
Qualitative findings
Characteristics of interview participants
31 mothers who received FP results for their infants were interviewed at T1 and 35 mothers were interviewed one year later, at T2. Of those interviewed at T2, 23 were new participants and 12 were interviewed at T1 and comprise a longitudinal sub-sample.
The lived experience
From 31 T1 qualitative interviews, we identified two major themes. The first relates to the nature of the distress that was experienced. From mothers' perspectives, receiving the notification phone call was frightening. Having been home from hospital with an apparently healthy baby and having perceived their discharge and non-involvement with the health care system as a "clean bill of health," it was alarming to learn that their child might have a chronic illness. Mothers reasoned that receiving this news on the heels of their own post-partum recovery likely added to the intensity of their response. Following receipt of this unexpected information, mothers attributed unusual newborn behavior (e.g. congestion, spit up, raspy breathing) to a possible diagnosis of CF, described a process of symptom seeking (e.g. licking the baby to gauge "saltiness"), and a fear of living a life with a child with a chronic illness (Table 4) . Among 23 new participants interviewed at T2, most reported similar distress in retrospect, but few reported ongoing distress. Of the 12 longitudinal participants, 3 reported a persistence of the distress that was reported at T1.
The second major theme relates to how the screening and tertiary care systems -and various players within this coordinated system -were valued by mothers and worked to mitigate the distress that was experienced. Mothers placed tremendous value on the fact that time to confirmatory testing was quick (generally <48 hours). They valued the active coordination of their care; specifically, being given a time and location to attend for confirmatory testing.
While mothers had mixed views about the importance of pre-test NBS education, mothers valued what they experienced as clear, calm, and sensitive communication from the involved heath care providers at both notification and confirmatory points in time (Table 4) .
Discussion
Using mixed methods, we provide a unique contribution to unresolved questions of psychosocial response to FP NBS results. A first key finding is that measures of psychosocial harm related to anxiety, distress, vulnerability and uncertainty were not increased in mothers of infants with FP results in the early newborn period or one year later. While no signal of harm was detected on these psychometric tools, a majority of mothers agreed that the FP experience had been the "scariest time in their lives" and reported worry about future family planning for their carrier infants. Similarly, in interviews, mothers of infants with FP results recalled distress during the notification and diagnostic follow-up periods, stemming from the unexpected nature of the information, symptom-seeking, and a fear of chronic disease. For most, distress did not persist one year later.
Our second key finding relates to the NBS system itself. Given longstanding concern about the risk of psychosocial harm in families of infants with FP results, NBS programs seek to mitigate potential distress. [52] [53] [54] [55] [56] [57] [58] Specifically, Ontario has developed a notification system that aims to minimize delay to confirmatory testing, provides point of care fact sheets to health professionals who are communicating results to parents and responding to questions, and aims to achieve a partnership with primary care providers who often play an initial notification role.
Our qualitative data indicate that parents valued this carefully structured screening system and perceive its role in mitigating FP-related distress. More specifically, parents valued the short waiting period preceding confirmatory testing. While measurable psychosocial distress has been identified among parents of screen positive infants, this may be associated with the longer waiting periods for confirmatory testing that were experienced in earlier years of CF NBS.
9,59-61
The absence of such distress on similar tools used herein underscores the importance of short waiting periods (i.e. <48 hours) for optimal patient experience. Additionally, mothers were content to defer to the screening system for logistics pertaining to follow-up and reflected favorably on provider communication and education strategies, whether offered by primary care providers or NBS program-affiliated genetic counselors.
We acknowledge several limitations. Since our study attracted a well-educated cohort of mothers that may have been better equipped to understand this experience, our findings may not be generalizable to mothers with less education. Others have reported an important link between knowledge/understanding of NBS results and psychosocial response 9, 15 so our findings must be considered in this light. Moreover, mothers of FP infants who are confirmed to be carriers may respond favorably to the receipt of this reproductive risk information. 10 The majority of our cohort represents the experience of mothers of carrier infants, possibly limiting the generalizability of these results to mothers of FP non-carriers. Second, our qualitative interviews were designed as two cross-sectional interviews, so did not actively probe change over time. Finally, the results may not be applicable to other disease screen positive populations.
Limitations notwithstanding, our mixed methods approach enables an enhanced understanding of maternal response to FP NBS results. While our findings from selected psychometric tools align with previous studies that report minimal adverse psychosocial sequelae, [9] [10] [11] other survey and qualitative findings suggest that parents experience distress and depend on the support provided by a well-structured screening system. Parental reflections on the role of the screening system in mitigating potential distress are novel and confirm the need for investment in centralized, well-coordinated, efficient screening systems in all jurisdictions to optimize patient experiences and outcomes.
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We thank Dr. Rahim Moineddin for his support with statistical analyses. 33 Used to assess impact of newborn diagnosis and as a measure of adjustment over time. [34] [35] [36] [37] [38] [39] Has not been used in NBS research CVS (8-items) 40 4-point scale from 'strongly disagree' to 'strongly agree' Total scores range from 0-24. In a clinical population, scores ≥ 10 indicate elevated perceptions of vulnerability; Internal consistency, test-retest reliability and validity are well demonstrated 40 Used in NBS research to measure response to positive NBS results [41] [42] [43] PPUS (4 items) 44 5-point scale from 'strongly agree' to 'strongly disagree'
Measures the uncertainty parents experience related to their child's illness; higher scores indicate greater perception of uncertainty. Internal consistency, testretest reliability and validity demonstrated 44 ; modified as per Table 3 Used to gauge perceived parental uncertainty between identification of symptoms in a child and point of diagnosis. [45] [46] [47] Has not been used in NBS research MWS (10-item ) 48 4-point scale; worry ' most of the time', 'often', 'sometimes', and 'not at all' Internal consistency, test-retest reliability and validity demonstrated 48 ; modified as per Table 3 Used for mothers of children with chronic illness. 48 Hasnot been used in NBS research *p < .05; ** p < .019; : t-tests performed on log transformed scale data, descriptive statistics reported on raw data; ~T 1 participants completed survey when infants was 2 months of age; T2 survey completed 1 year later; ^BSI: t scores reported; measured 15 items to gauge general distress, using the depression and obsessive behaviors sub-scales and l 4 additional items to generate Global Severity Index 33,37-39 ^^PPUS: eliminated items related to medical treatment, attitudes toward health care providers, and items not specifically about uncertainty in health and illness; revised items to be about babies and to be CFspecific ^^^M WS: changed "health condition" to "health", removed 4 items specific to being sick/using medication, added 3 items to suit context of genetics; Mann-Whitney U test performed due to the nonparametric nature of data; MWS means reported for consistency with other measures; MWS_revised: 9-item version with the item re: worry about children's choices about having children removed. 
Mothers experience distress in the early days
The news is distressing Just as you think everything is going so perfectly, you hear this… it is so scary; you always think it happens to other people... (205) I just shut down. I didn't hear anything. She kept talking and I could tell she was trying to calm me down, but I couldn't hear anything she was saying. (015) Well, I guess it kind of blew me out of the water…we signed the form in the hospital… but didn't know anything really about it, so forgot about it. So, when the call came it knocked me on my butt... (050) The news triggers symptom monitoring All I kept saying was 'she's got cystic fibrosis. That's why...' She was really congested… I said, 'oh my god, this is why she's this. This is why this happened. This is why she keeps throwing up when she eats. (015) No, we just spent the two days looking up symptoms, trying to find reasons that would explain. She had a really, really positive outlook. And, she was really calm. And, you know, I don't... it wouldn't have made it any worse or better hearing it from my family doctor or something, or somebody that I knew... You know, the way she presented the information I think made a huge difference even though I didn't... I've never spoken to her before. (153) You could tell that she just knew what she was doing, very routine. She was comfortable with babies. Like, she was excited. She was talking to our son. Like, we hadn't even started talking to our kid. And, it was just a very, like, upbeat feeling. And, she was, like, "yeah, stay in here as long as you need to" and, like, just very warm...and comfortable." (035) And, it was certainly my experience that everybody was sensitive... I felt completely supported. And, I felt like for all I knew [she] could have been there only for me; and that's the way she made you feel. Like, "I'm just here for you and it doesn't matter; anybody can walk into my office right now. It doesn't matter. I'm talking to you. And, I think she was great at that. And, I think if your other folks are making a... are like her, I don't think you have a problem. And, I mean, doctors or whoever making that call, as long as parents feel supported and that you care and it's not a... this is not routine. It may be routine to you; it's not routine to me. That's the only thing. (141) The role of early information about newborn screening outcomes is unresolved You know, if my OB would have sat down with me and spoken to me for five, ten minutes about what the results would be and, you know, potential results and what would happen, what the steps would be if this or that happened; yes, the pregnant woman freaks out, but it's almost... it's better to be kind of forewarned I think. It gives you time to think about it. I don't know. Instead of just somebody coming in and, you know, doing the prick test and then two weeks later you get a phone call, ta da! (153) And, I've thought a lot about this since. I'm not so sure I would have had it any other way. That's kind of the problem because you kind of forget about it. But, if nothing was wrong, so say with the second child, I'm not so sure I'd want to be thinking about, you know, a phone call that may come. Of course I will now because I've gone through it, but I'm not so sure what the right answers are. At first I thought it would have been nice to be reminded when we left the hospital that those... that screening was being completed, but now that I've sat and thought about it I'm not so sure I would have wanted to know that either. So, I would say we were completely shocked. I guess part of the problem too is when we signed that form we didn't really know what was being tested either. And, you know, we could have looked it up for sure and I've since looked it up, but I had no idea what we were even... was the potential to come up. (050)
